Poitiers

• BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, … Recruiting
  2024-520128-27-00 4 2026-03-04 colorectal adenocarcinoma
• Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes Recruiting
  2025-521670-34-00 5 2026-03-04 Acute coronary syndrome (ST-elevation myocardial infarction [STEMI] or
• Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combin … Recruiting
  2023-506291-28-00 5 2026-03-02 Patient with locally advanced/metastatic, MSI-H/dMMR gastric cancer
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum … Recruiting
  2025-520897-21-00 10 2026-02-25 Multiple Myeloma
• PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai … Recruiting
  2025-522108-26-00 4 2026-02-19 métastatique colorectal cancer
• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Pancreatic cancer first-line NALIRIFOX optimization with 5-FU maintenance and role of antibiotics and microbiota exploration in second-line … Recruiting
  2024-517766-41-00 4 2026-02-17 Patients with metastatic pancreatic ductal adenocarcinoma.
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated … Recruiting
  2024-515948-23-00 5 2026-02-06 Advanced pulmonary or gastroenteropancreatic poorly differentiated neu
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc … Recruiting
  2024-515023-11-00 5 2026-01-22 Advanced Clear Cell Renal Cell Carcinoma
• FILOWM4-WaZaBi: "Open label phase 2 study evaluating the efficacy and tolerance of a zanubrutinib and BGB-11417 combination in patients prev … Recruiting
  2023-505781-28-00 4 2026-01-20 Patients with Waldenstrom macroglobulinemia and have received at least
• Efficacy of intravesical oxybutynin in children with neurogenic bladder dysfunction: A randomized, prospective controlled multi-center trial … Recruiting
  2022-501902-36-00 5 2026-01-15 spina bifida
• GRAALL 2024 - A 3-cohort Randomized Study evaluating the role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Tran … Recruiting
  2024-511437-35-00 10 2026-01-05 Patients aged 18-65 years old with newly diagnosed previously untreate
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• Open label phase II study evaluating the efficacy and safety of the combination of tagraxofusp and venetoclax in treatment-naive blastic pla … Recruiting
  2024-511003-42-00 4 2025-12-11 BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASMS
• Dapagliflozine for cardio-renal protection at ICU discharge Recruiting
  2024-510941-32-00 5 2025-12-02 Adult patients discharged alive from ICU with a decreased eGFR, and/or
• Risk-adapted adjuvant chemotherapy guided by the tumour stage for operated pancreatic adenocarcinoma following neoadjuvant chemotherapy with … Recruiting
  2024-519048-33-00 10 2025-11-25 resected pancreatic adenocarcinoma
• A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus … Recruiting
  2024-519590-19-00 4 2025-11-25 PD-L1 positive advanced colorectal cancer
• Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced … Recruiting
  2024-519871-24-00 10 2025-11-11 Breast cancer
• Clinical trial evaluating the activity of zanidatamab for the treatment of patients with solid tumors with an alteration of the HER2 gene Recruiting
  2025-522169-31-00 4 2025-10-30 Adult Patients with HER2-IHC3+ selected solid cancers (endometrial, co
• AKAPI: Amikacin Liposome Inhalation Suspension for treatment of Mycobacterium xenopi pulmonary infection: A prospective controlled open-labe … Recruiting
  2023-506843-40-00 5 2025-10-29 Mycobacterium xenopi pulmonary infection
• Testing ivonescimab in combination with standard chemotherapy in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients Recruiting
  2025-520694-39-00 4 2025-10-24 Metastatic or locally advanced irresectable (stage IV) gastric cancer
• A Phase 1 Study of NDI-219216 in Patients with Advanced Solid Tumors with and without Microsatellite Instability and/or Deficient Mismatch R … Recruiting
  2025-522774-36-00 1 2025-10-24 Advanced solid tumors
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax (ABBV-453) Alone or in Combination With Subcutaneous and … Recruiting
  2024-517140-65-00 9 2025-10-23 Multiple Myeloma (MM).

Showing 121–144 of 615 trials